Skip to main navigation Skip to search Skip to main content

The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis

Michael Hughes*, Suiyuan Huang, John D Pauling, Maya Sabbagh, Dinesh Khanna

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

13 Citations (Scopus)

Abstract

Raynaud's phenomenon (RP) is a cardinal feature of systemic sclerosis (SSc) and manifests with pain, digital colour change, sensory symptoms, and impaired function. SSc-RP is exacerbated by cold exposure (RP 'attacks') but many patients report persistent symptoms of background digital ischaemia. The aim of our study was to examine the significance of RP with digital colour change with or without symptoms, and persistent colour change in between attacks. Patients with SSc responses were obtained from the Patient Survey of experiences of Raynaud's Phenomenon (PASRAP). We enquired about symptoms associated with Raynaud's attacks, and persistent symptoms in between attacks. Data were analysed as descriptive statistics with appropriate parametric/non-parametric testing. Relevant PASRAP survey question data from 747 evaluable SSc patients from across three continents were analysed. Isolated colour change was rare (29/484, 6%). Digital ulcers were more common in SSc-RP associated with other sensory symptoms (42.1% vs. 24.1%, P=0.057) and more readily treated with phosphodiesterase-type 5 inhibitors (22.5% vs. 10.3%%, P=0.124). Over one-third of patients (n=92/239, 38%) reported persistent colour change in between Raynaud's attacks. Patients with persistent colour change were more likely to have pulmonary arterial hypertension (15.2% vs. 7.5%, P=0.057) and be treated with calcium channel blockers (54.3% vs. 39.0%, P=0.021). SSc-RP with colour change and other symptoms and/or or persistent decolourisation in between attacks were more likely to have vascular complications of SSc and be treated with vascular therapies. Future research should explore the judicious use of vascular therapies as a potential form of disease modification in SSc.
Original languageEnglish
Pages (from-to)3049-3054
Number of pages6
JournalClinical Rheumatology
Volume41
Issue number10
Early online date18 May 2022
DOIs
Publication statusPublished - 1 Oct 2022

Bibliographical note

Publisher Copyright:
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Keywords

  • Calcium Channel Blockers/therapeutic use
  • Humans
  • Phosphoric Diester Hydrolases/therapeutic use
  • Raynaud Disease/etiology
  • Scleroderma, Systemic
  • Skin Ulcer/etiology

Fingerprint

Dive into the research topics of 'The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis'. Together they form a unique fingerprint.

Cite this